What's driving the Cancer Gene Therapy Market trends? Key Company Profiled Amgen, Aduro Biotech, OncoGeneX, GlobeImmune, Inc., New Link Genetics., MolMed S.p.A, ZioPharm Oncology, Gradalis

Market Study Report LLC provides a detailed overview of Cancer Gene Therapy market with respect to the pivotal drivers influencing the revenue graph of this business sphere. The current trends of Cancer Gene Therapy market in conjunction with the geographical landscape, demand spectrum, remuneration scale, and growth graph of this vertical have also been included in this report.

Globally, rising cancer prevalence will increase demand for gene therapy as the effective personalized treatment choice. According to WHO, cancer incidence is projected to rise by 50% to reach 15 million by the end of this decade. This alarming increase in number of patients necessitates this as a potential treatment approach addressing the growing global burden of the disease. Cancer Gene Therapy Market size is expected to exceed USD 4.3 billion by 2024; as per a new research report.

Request a sample of this premium report at: https://www.marketstudyreport.com/request-a-sample/467801/?utm_source=Openpr.com-SP

Increased adoption of emerging genomic technologies such as NGS and high density micro array coupled with favorable government initiatives will fuel global cancer gene therapy market size. For instance, CDC supports nationwide screening programs for control of breast, cervical and colorectal cancer among low-income women with little or no health insurance. However, high cost of development lack of reimbursement and regulatory processes will restrain industry growth.

U.S. led the industry owing to increased R&D funding and other government initiatives. Growing number of biotech companies are engaging in R&D and clinical trials of gene therapy products. Increased demand for DNA vaccines and increasing interest of venture capitalists to invest in commercialization of gene therapies will trigger industry expansion.

Growing number of clinical trials and availability of wide range of genes and vectors used in these trials will enable emergence of new treatment modalities to help make cancer a manageable disease. By the end of 2012, the number of clinical trials crossed 1,800 worldwide. Adenoviral vector remains as the most common oncology application due to its competent nuclear mechanism and low pathogenicity. It is widely used in replacement approaches, suicide and gene-based immunotherapy, and syndicate with chemotherapy and is anticipated to grow at 20% CAGR.

Retroviral vector-mediated gene transfer dominated the development by enabling the conversion of single stranded RNA into a double stranded DNA molecule, which steadily integrates into the target cell genome. These vectors are used to permanently modify the host cell nuclear genome and will register a robust growth of over 20%.

Request a discount on standard prices of this premium report at: https://www.marketstudyreport.com/check-for-discount/467801/?utm_source=Openpr.com-SP

China cancer gene therapy market size attributed to over 35% APAC revenue in 2015. With the launch of Gendicine and increasing healthcare expenditure and robust R&D facilities will enable industry growth.

Key insights from the report include:

U.S. cancer gene therapy market share accounted for over 95% regional revenue in 2015, with market size of USD 235 million and a forecast to grow at 20.9% CAGR.

UK was over USD 92.0 million in 2015, and will grow at 20.8% CAGR owing to increasing incidence of cancer and adoption of advanced treatment methods.

China market size was valued at USD 99.6 million in 2015 and growth expectations of 21% CAGR over the forecast years.

Key players include SiBiono, Altor Bioscience Corporation, Shanghai Sunway Biotech company limited, Amgen, BioCancell, OncoGeneX, Aduro Biotech, GlobeImmune, Inc., New Link Genetics., ZioPharm Oncology, MolMed, GENELUX, Gradalis, MultiVir.

The industry is highly fragmented and is dominated by several small biotech firms collectively accounting for over 80% of cancer gene therapy market pipeline. Major growth strategies adopted by these small firms include, technology transfer, licensing and commercialization deals, strategic collaborations and mergers and acquisitions to retain their industry position.

Table of Content:

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.1.1. Initial data exploration

1.1.2. Statistical modeling and forecast

1.1.3. Industry insights and validation

1.1.4. Research scope & assumptions

1.2. Data Sources

Chapter 2. Executive Summary

2.1. Cancer genetics industry 360 degree synopsis, 2012 - 2024

2.1.1. Business trends

2.1.2. Regional trends

2.1.3. Application trends

Chapter 3. Cancer Gene Therapy Industry Insights

3.1. Industry segmentation

3.2. IIndustry Size and forecast, 2012 - 2024

3.3. Industry Impact forces

3.3.1. Growth drivers

3.3.1.1. Technological advancements

3.3.1.2. Increased adoption of nanotechnology

3.3.1.3. Favorable government regulations

3.3.2. Industry pitfalls & challenges

3.3.2.1. High cost of cancer genetherapy

3.4. Growth potential analysis

3.5. Porter's analysis

3.6. Key opportunities prioritized, 2015

3.7. PESTEL analysis

3.8. Regulatory Landscape

3.8.1. U.S.

3.8.2. EU

3.8.3. China

3.9. Scientific and Ethical issues in Gene Therapy

3.10. Competitive landscape, 2015

3.11. Pipeline Analysis by cancer type

3.11.1. Head and Neck Cancer Pipeline Analysis

3.11.2. Breast Cancer Pipeline Analysis

3.11.3. Gastro Intestinal Cancer Pipeline Analysis

3.11.4. Gentiourinary Cancer Pipeline Analysis

3.11.5. Gynecological Cancer Pipeline Analysis

3.11.6. Haemotological Cancer Pipeline Analysis

3.11.7. Neurologic Cancer Pipeline Analysis

3.11.8. Respiratory Cancer Pipeline Analysis

3.11.9. Skin Cancer Pipeline Analysis

Chapter 4. Cancer Gene Therapy Insights

4.1. Cancer gene therapy market share by therapy, 2015 & 2024

4.2. Gene Induced Immunotherapy

4.2.1. Market estimates and forecast, 2012-2024 (USD Million)

4.2.2. Delivery of cytokine gene

4.2.2.1. Market estimates and forecast, 2012-2024 (USD Million)

4.2.3. Delivery of tumor antigen gene

4.2.3.1. Market estimates and forecast, 2012-2024 (USD Million)

4.3. Oncolytic Virotherapy

4.3.1. Market estimates and forecast, 2012-2024 (USD Million)

4.3.2. Adenoviruses

4.3.2.1. Market estimates and forecast, 2012-2024 (USD Million)

4.3.3. Lentiviruses

4.3.3.1. Market estimates and forecast, 2012-2024 (USD Million)

4.3.4. Retrovirus

4.3.4.1. Market estimates and forecast, 2012-2024 (USD Million)

4.3.5. Adeno Associated Virus

4.3.5.1. Market estimates and forecast, 2012-2024 (USD Million)

4.3.6. Herpes Simplex Virus

4.3.6.1. Market estimates and forecast, 2012-2024 (USD Million)

4.3.7. Alphavirus

4.3.7.1. Market estimates and forecast, 2012-2024 (USD Million)

4.3.8. Vaccinia Virus

4.3.8.1. Market estimates and forecast, 2012-2024 (USD Million)

4.3.9. Simian Virus

4.3.9.1. Market estimates and forecast, 2012-2024 (USD Million)

For more information on this report at: https://www.marketstudyreport.com/reports/cancer-gene-therapy-market/?utm_source=Openpr.com-SP

Related Report:

Global Gene Therapy Market Size, Status and Forecast 2019-2025

Gene therapy is an experimental treatment that involves introducing genetic material into a person?s cells to fight or prevent disease. Researchers are studying gene therapy for a number of diseases, such as severe combined immuno-deficiencies, hemophilia, Parkinson's disease, cancer and even HIV, through a number of different approaches. A gene can be delivered to a cell using a carrier known as a vector. The most common types of vectors used in gene therapy are viruses. The viruses used in gene therapy are altered to make them safe, although some risks still exist with gene therapy. The technology is still in its infancy. Today, Gene Therapy is used for Cancer Diseases, Hematological Disease and Hereditary Disease. Cancer Diseases is the largest application of Gene Therapy and its market share exceed 78% in 2018.

https://www.marketstudyreport.com/reports/global-gene-therapy-market-size-status-and-forecast-2019-2025?utm_source=RR-SP

Contact Us:
Market Study Report LLC
4 North Main Street,
Selbyville, Delaware 19975
USA
Phone: 1-302-273-0910
US Toll Free: 1-866-764-2150
Email: sales@marketstudyreport.com
Website: https://www.marketstudyreport.com
Blog: https://www.marketstudyreport.com/blog/

About Us:
Marketstudyreport.com allows you to manage and control all corporate research purchases to consolidate billing and vendor management. You can eliminate duplicate purchases and customize your content and license management.

This release was published on openPR.